ArticleThe Lancet. Infectious diseases2022

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.

Norbert Ndjeka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.